Molecular Alterations in Thyroid Cancer – with Special Focus on Diagnosis, Prognosis and Treatment

Dear Colleagues,

Thyroid cancer is the most common endocrine malignancy with an annual incidence of about 60,000 cases in the US and shows an increased incidence globally. The disease entity is multifaceted, and although the majority of well-differentiated forms of thyroid cancer (papillary thyroid cancer, PTC, and follicular thyroid cancer, FTC) exhibit good prognosis, other forms of thyroid cancer are often associated with dismal outcomes (poorly differentiated thyroid cancer, PDTC, and anaplastic thyroid cancer, ATC). The underlying genetic mechanisms driving thyroid cancer is only partly understood, but the advent of next-generation sequencing techniques has greatly facilitated the detection of recurrent genomic alterations of importance for disease development—of which some could be of direct clinical value.

This Special Issue will focus on molecular studies aimed at providing aid to three commonly encountered clinical dilemmas, namely (1) the diagnostic predicaments in thyroid cancer (most notably―but not limited to―the distinction of benign and malignant follicular thyroid tumors), (2) the enablement to prognosticate thyroid cancer (for example, to pinpoint the subset of thyroid cancer that recur and/or spread to distant sites) and (3) the therapeutic quandaries regarding metastatic thyroid cancer and less differentiated forms of the disease (PDTC, ATC). Further, submissions aimed at increasing our understanding of inherited forms of thyroid cancer are also warmly welcome.

Dr. Carl Christofer Juhlin
Dr. Adam Stenman
Prof. Dr. Jan Zedenius
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.